Symptom Experience and Self-management After Haematopoietic Stem Cell Transplantation

NCT ID: NCT01275534

Last Updated: 2013-01-17

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 375 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2010-11-30
• Study Completion Date: 2012-11-30

Brief Summary

In the study PROVIVO, a patient reported outcome instrument consisting of items from the PRO-CTCAE item bank measuring symptom experience of long-term survivors after allogeneic hematopoietic stem cell transplantation (SCT) will be developed. The instrument development is based on cognitive patient interviews, a survey of hematology experts and a literature review. In a subsequent cross-sectional study phase, the instrument will be validated in a sample of 300 allogeneic stem cell recipients and by the use of additional self report instruments it will be possible to explore how subjective symptom experience, problems in self-management and presence of late effects are connected.

Detailed Description

Long-term survivors after allogeneic SCT are presumably at a life-long increased risk for developing various adverse side effects; also termed 'late effects'. Late effects may appear months or years after treatment has ended, can persist chronically and may be experienced as rather distressing and burdensome. Since most late effects are only experienced subjectively in the form of physical and mental symptoms and are seldom captured during objective clinician-based evaluations, using self-report instruments is important for the early detection, management and alleviation of these symptoms. The collection of self-report data in studies and clinical practice is strongly recommended by the National Cancer Institute (NCI): they developed a Patient-Reported Outcomes bank based on the well established Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Besides managing symptoms associated with late-effects, patients with SCT are also requested to manage their emotions associated with having a chronic illness, their new life roles in order to have a meaningful, fulfilling life, and their medical regimen, in view of taking medications, smoking cessation, regularly exercising and monitoring for signs of infection. However, evidence investigating the prevalence of problems related to these complex set of self-management tasks is scarce.

Aims:

• To translate the PRO-CTCAE items into German in a culturally-sensitive way and to develop the content of a self-report instrument measuring symptom experience after allogeneic SCT
• To validate the newly developed scale and assess its psychometric properties
• To examine self reported symptom experience and objective measured late effects in 300 adult survivors ≥ 1 year after SCT
• To describe self-management behaviours in 300 adult survivors ≥ 1 year after SCT
• To assess the relationship between symptom experience and objective burden of late effects, survivors' perception of late effects and self-management in view of managing emotions, managing new life roles and managing medical and health tasks in 300 adult survivors ≥ 1 year after allogeneic SCT

Conditions

Hematologic Neoplasms

Study Design

• Observational Model Type: CASE_ONLY
• Study Time Perspective: CROSS_SECTIONAL

Eligibility Criteria

Inclusion Criteria

• Having received allogeneic SCT for haematological disease
• ≥ 1 year of follow-up experience after treatment
• Ability to understand and read German and having signed the written informed consent

Exclusion Criteria

• Patients with psychiatric illness that in the opinion of physicians prevent them from participating
• Visual and/or hearing impairment which hinders participation in an interview/fill-out a questionnaire
• Being illiterate
• Actual acute care hospitalization stay at interview date
• Terminal illness

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Basel

OTHER

Sponsor Role: collaborator

University Hospital, Zürich

OTHER

Sponsor Role: collaborator

University Hospital, Basel, Switzerland

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Sabina De Geest, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Basel

Locations

University Hospital Basel

Basel, , Switzerland

University Hospital Zürich

Zurich, , Switzerland

Countries

Switzerland

References

Kirsch M, Mitchell SA, Dobbels F, Stussi G, Basch E, Halter JP, De Geest S. Linguistic and content validation of a German-language PRO-CTCAE-based patient-reported outcomes instrument to evaluate the late effect symptom experience after allogeneic hematopoietic stem cell transplantation. Eur J Oncol Nurs. 2015 Feb;19(1):66-74. doi: 10.1016/j.ejon.2014.07.007. Epub 2014 Sep 1.

Reference Type: DERIVED

PMID: 25190633 (View on PubMed)

Other Identifiers

EKBB 264-10

Identifier Type: -

Identifier Source: org_study_id